| 000 | 01190 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514035240.0 | ||
| 264 | 0 | _c20021126 | |
| 008 | 200211s 0 0 eng d | ||
| 022 | _a1060-0280 | ||
| 024 | 7 |
_a10.1345/aph.1A231 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFurler, Michelle D | |
| 245 | 0 | 0 |
_aCost impact of switching histamine(2)-receptor antagonists to nonprescription status. _h[electronic resource] |
| 260 |
_bThe Annals of pharmacotherapy _c |
||
| 300 |
_a1135-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aHistamine H2 Antagonists _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNonprescription Drugs _xadministration & dosage |
| 650 | 0 | 4 | _aPharmacoepidemiology |
| 650 | 0 | 4 | _aUnited Kingdom |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aRolnick, Mark S | |
| 700 | 1 | _aLawday, Kathleen S | |
| 700 | 1 | _aMak, Miranda W | |
| 700 | 1 | _aEinarson, Thomas R | |
| 773 | 0 |
_tThe Annals of pharmacotherapy _gvol. 36 _gno. 7-8 _gp. 1135-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1345/aph.1A231 _zAvailable from publisher's website |
| 999 |
_c11980984 _d11980984 |
||